PRIMARY RESULTS OF LONG-TERM DYNAMIC MONITORING OF CHILDREN WITH BRONCHIAL ASTHMA OF UNCONTROLLED SEVERE PERSISTENT COURSE

Background. Patients registers help obtain the latest information about the clinical course of a disease, safety and effectiveness of the medical technology. Objective: Our aim was to analyze the efficiency and safety of omalizumab with children suffering from uncontrolled severe persistent bronchial asthma (BA) according to the data of the developed register.

Methods.  A register of patients with severe asthma of uncontrolled course receiving omalizumab in addition to basic therapy has been developed.

Results. Results of treatment of 101 children aged 6–17 have been analyzed. The duration of therapy with omalizumab lasted from 1 to 85 months, with a median of 16 (10; 44) months. The drug was used in doses of 75 to 600 mg, with a median of 300 (225; 375) mg. The therapy with omalizumab allowed achieving a better control of the disease (AST test prior to start of therapy — 14 (11; 17) points, in 1 year — 20 (13; 25); p < 0,001); reduction of the volume of daily base therapy (prior to start of therapy, average dose of inhaled corticosteroids in terms of fluticasone was 629 ± 304 mg (n = 15), in 4 years — 524 ± 342 mg; p = 0.065); reduction of the number of aggravations and the need to use short-effectiv   2-agonists.  No adverse systemic effects of the introduction of genetically engineered biological drugs have been found.

Conclusion. Register of patients with severe persistent asthma can be used as a tool for long-term  monitoring and integrated assessment of the efficiency and safety of therapy.

1. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12. doi: 10.1186/1939-4551-7-12.

2. globalasthmareport.org [Internet]. The Global Asthma Report 2014 [cited 2016 Sep 29]. Available from: http://www. globalasthmareport.org/burden/burden.php.

3. Annesi-Maesano I, Lundback B, Viegi G. Respiratory Epidemiology. Series: ERS Monograph. European Respiratory Society; 2014. p. 119-121. doi: 10.1183/2312508X.erm6514.

4. cdc.gov [Internet]. U.S. Department of health & human services, Centers for Disease Control and Prevention, National Center for Health Statistics. National surveillance of asthma: United States, 2001-2010. Washington, DC: U.S. Government Printing Office; 2012 [cited 2016 Nov 29]. Available from: https://www.cdc.gov/nchs/data/series/sr_03/sr03_035.pdf.

5. Mellon M, Parasuraman B. Pediatric asthma: improving management to reduce cost of care. J Manag Care Pharm. 2004; 10(2):130-141. doi: 10.18553/jmcp.2004.10.2.130.

6. cdc.gov [Internet]. Centers for Disease Control and Prevention, National Center for Health Statistics. Asthma Prevalence, Health Care Use and Mortality: United States, 2003-2005 [cited 2016 Sep 29]. Available from: http://www.cdc.gov/nchs/data/hestat/asthma03-05/asthma03-05.htm.

7. sign.ac.uk [Internet]. Scottish Intercollegiate Guidelines Network. SIGH/BTS British guideline on the management of asthma. Asthma properties: influencing the agenda. February 2013 [cited 2016 Sep 29]. Available from: http://www.sign.ac.uk/pdf/sign101_ asthma_workshops_report.pdf (Available 29.09.2016).

8. Fuhlbrigge AL, Guilbert T, Spahn J, et al. The influence of variation in type and pattern of symptoms on assessment in pediatric asthma. Pediatrics. 2006;118(2):619-625. doi: 10.1542/peds.2005-2963.

9. Darveaux J, Busse WW. Biologics in asthma — the next step towards personalized treatment. J Allergy Clin Immunol Pract. 2015;3(2):152-161. doi: 10.1016/j.jaip.2014.09.014.

10. Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491-502. doi: 10.1007/s40272-014-0107-z.

11. Abraham I, Alhossan A, Lee CS, et al. Real-life effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016;71(5):593-610. doi: 10.1111/all.12815.

12. Kuprys-Lipinska I, Majak P Molinska J, Kuna P. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulm Med. 2016;16(1):61. doi: 10.1186/s12890-016-0224-2.

13. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014;108(12):1723-1732. doi: 10.1016/j.rmed.2014.10.007.

14. Korn S, Hubner M, Hamelmann E, Buhl R. [The German severe asthma registry. (In German).] Pneumologie. 2012;66(6):341-344. doi: 10.1055/s-0032-1308908.

15. ginasthma.org [Internet]. 2016 GINA Report, Global Strategy for Asthma Management and Prevention [cited 2016 Sep 29]. Available from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/.

16. Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. p. 47.

17. Вишнёва Е.А., Намазова-Баранова Л.С., Антонова Е.В., Смирнов В.И. Первая отечественная информационная система — база данных клинических случаев пациентов детского возраста с персистирующей бронхиальной астмой // Педиатрическая фармакология. — 2015. — Т. 12. — № 1 — С. 18-21. [Vishneva EA, Namazova-Baranova LS, Antonova EV, Smirnov VI. The first Russian information system — database of clinical cases of persistent bronchial asthma in pediatric patients. Pediatric pharmacology. 2015;12(1):18-21. (In Russ).] doi: 10.15690/pf.v12i1.1242.

18. rlsnet.ru [интернет]. Энциклопедия лекарств и товаров аптечного ассортимента. Омализумаб (Omalizumab): инструкция, применение и формула [доступ от 21.09.2016]. Доступ по ссылке http://www.rlsnet.ru/mnn_index_id_3748.htm.

19. Авдеев С.Н. Опросник ACQ — новый инструмент оценки контроля над бронхиальной астмой // Пульмонология. — 2011. — Т. 8. — № 2 — С. 93-99. [Avdeev SN. Oprosnik ACQ — novyi instrument otsenki kontrolya nad bronkhial'noi astmoi. Pul'monologiya. 2011;(2):93-99. (In Russ).]

20. qoltech.co.uk [Internet]. Standardised paediatric asthma quality of life questionnaire (PAQLQ(S) [cited 2016 Nov 13]. Available from: https://www.qoltech.co.uk/paqlq_s.html.

21. Barnes N, Menzies-Gow A, Mansur AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK realworld study. J Asthma. 2013;50(5):529-536. doi: 10.3109/02770903.2013.790419.

22. Lopez Tiro JJ, Contreras EA, Del Pozo ME, et al. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol (Madr). 2015;43(2):120-126. doi: 10.1016/j.aller.2013.11.008.

23. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104(10):1410-1416. doi: 10.1016/j.rmed.2010.04.013.

24. Vieira T, de Oliveira JF, da Graca Castel-Branco M. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol (Madr). 2014;42(1):3-10. doi: 10.1016/j.aller.2012.07.006.

25. Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma. 2012;49(1):78-82. doi: 10.3109/02770903.2011.637598.

26. Gouder C, West LM, Montefort S. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm. 2015;37(1):36-43. doi: 10.1007/s11096-014-0034-7.

27. Gibson P, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016;46(9):1054-1062. doi: 10.1111/imj.13166.

28. Chen HC, Huang CD, Chang E, Kuo HP. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulm Med. 2016;16:3. doi: 10.1186/s12890-015-0156-2.

29. Tzortzaki EG, Georgiou A, Kampas D, et al. Long-term omali-zumab treatment in severe allergic asthma: the South-Eastern Mediterranean real-life experience. Pulm Pharmacol Ther. 2012; 25(1):77-82. doi: 10.1016/j.pupt.2011.11.004.

30. De Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296-301. doi: 10.3109/02770903.2012.757780.

31. Vennera Mdel C, Perez De Llano L, Bardagi S, et al. Omalizumab therapy in severe asthma: experience from the Spanish registry — some new approaches. J Asthma. 2012;49(4):416-422. doi: 10.3109/02770903.2012.668255.

32. Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141-1151. doi: 10.1016/j.rmed.2013.04.017.

33. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224-1233. doi: 10.1183/09031936.00149812.

34. Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856-859. doi: 10.1183/09031936.00008115.

35. Куличенко Т.В., Намазова-Баранова Л.С., Торшхоева Р.М., и др. Aнти-IGE-терaпия тяжелой бронхиальной астмы у детей: двухлетний опыт // Педиатрическая фармакология. — 2010. — Т. 7. — № 3 — С. 57-65. [Kulichenko TV, Namazova-Baranova LS, Torshkhoeva RM, et al. Anti-IGE therapy for severe asthma in children: two-year trial. Pediatric pharmacology. 2010;7(3):57-65. (In Russ).]

36. Куличенко Т.В., Баранов А.А., Абелевич М.М., и др. Обобщенный анализ применения моноклональных антител к IgE в лечении бронхиальной астмы у детей в РФ // Педиатрическая фармакология. — 2011. — Т. 8. — № 2 — С. 50-56. [Kulichenko TV, Baranov AA, Abelevich MM, et al. Generalized analysis of monoclonal antibodies to IGE in the treatment of bronchial asthma in children in Russian Federation. Pediatric pharmacology. 2011;8(2):50-56. (In Russ).]

37. aap.org [Internet]. American Academy of Pediatrics. Chapter Quality Network (CQN) Asthma Program Request for Applications (RFA) [cited 2016 Sep 29]. Available from: http:/